A CAR-T cell therapy acquired by Celgene earlier this year could have a path forward in chronic lymphocytic leukemia (CLL), showing initial signs of efficacy in a small group of heavily pretreated patients with the blood cancer.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,